6th Antifibrotic Drug Development Summit (AFDD)

Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies.

From exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ, cross-disease, cross-discipline discussion forum is here to transform your fibrosis research.

Join 100+ industry super giants from Boehringer Ingelheim, Genentech, Gilead, Pfizer, Novartis, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development.

Tickets    https://go.evvnt.com/1241066-2?pid=2809 
Brochure https://go.evvnt.com/1241066-3?pid=2809 

Prices:
Industry - Conference + Workshop Day (Earlybird rates available) USD 3946.00
Industry - Conference Only (Earlybird rates available) USD 2599.00
Academics - Conference + Workshop Day (Earlybird rates available) USD 3246.00
Academics - Conference Only (Earlybird rates available) USD 2199.00
Solution Providers - Conference + Workshop Day (Earlybird rates available) USD 5696.00
Solution Providers - Conference Only (Earlybird rates available) USD 3599.00

Speakers: Adi Mor Chief Scientific Officer Chemomab, Akshay Krishnamurty Senior Scientist, Cancer Immunology Genentech, Andrew Leask Professor University of Saskatchewan, Andrzej Krolewski Senior Investigator Joslin Diabetes Centre, Anissa Kalinowski Chief Executive Officer Halo Biosciences, Anjali Pandey Senior Vice President Nonclinical R&D & Chemistry ARIA Pharmaceuticals, Anna Zargoska Senior Research Scientist II Gilead, Cheryl Nickerson-Nutter Vice President Research & Development Three Lakes Partners, Christian Hesslinger Senior Expert Translational Medicine & Biomarker Boehringer Ingelheim, Christina Wenglen Head of Research Anamar, David Lagares Director & Head of Matrix & Mechanobiology Program Massachusetts General Hospital, Elizabeth Redente Associate Professor National Jewish Health, Eric White Senior Clinical Program Lead Boehringer Ingelheim, Geoffrey Teixeira Head of Fibrosis Alentis Therapeutics, Haig Aghajanian Co-Founder & Vice President – Research Capstan Therapeutics, Harry Karmouty-Quintana Associate Professor University of Texas, Herman Steen Co-Founder & Chief Executive Officer BiOrion Technologies, Hind Lal Associate Professor University of Alabama at Birmingham, Ilya Korsunsky Instructor of Medicine Harvard Medical School, Jeff Biernaskie Professor University of Calgary, Jeremy O’Connell Chief Scientific Officer & Co-Founder Juvena Therapeutics, Ken Dower Senior Principal Scientist & Associate Fellow – Research Pfizer, Kevin Wei Assistant Professor Harvard University, Lee Borthwick Chief Operating Officer FibroFind, Lindsay McDonald Assistant Professor Medical University of South Carolina, Michael Underhill Professor University of British Columbia, Morten Karsdal Chief Executive Officer Nordic Bioscience, Peter Bunyard Head of Fibrosis Biology RedX Pharma, Philipp Tropberger Senior Principal Scientist Novartis, Richard Stratton Consultant & Senior Lecturer University College London, Rohan Manohar Associate Director – Discovery Biology Scholar Rock, Ryan Feaver Executive Director & Head of Exploratory Biology HemoShear, Shannon Turley Vice President, Immunology & OMNI Biomarker Discovery Genentech, Thomas Fabre Senior Scientist Pfizer, Will Richardson Assistant Professor of Bioengineering University of Arizona

Read More

View Less